A Clinical Trial to Evaluate the Effects of Rejuvaskin Eczema Body Wash and Skin Recovery Cream in Adults With Eczema-Prone Skin

A Clinical Trial to Evaluate the Effects of Rejuvaskin Eczema Body Wash and Skin Recovery Cream in Adults With Eczema-Prone Skin

This is a single-arm, open-label, decentralized (fully remote) clinical trial evaluating the tolerability and self-perceived skin effects of Rejuvaskin Eczema Body Wash and Skin Recovery Cream in 35 adults aged 18-65 with self-reported eczema-prone skin. Participants will use the body wash once daily in place of their usual cleanser, followed by the Skin Recovery Cream, for 4 consecutive weeks.

Inclusion Criteria:

• Adult women or men aged 18-65 years.
• Self-reported symptoms of eczema or eczema-prone skin (e.g., dryness, roughness, itching, irritation on the body).
• Visible signs of eczema such as dryness, roughness, or irritation on at least one part of the body at the time of enrollment.
• Willing to use Rejuvaskin Eczema Body Wash once daily as their primary body cleanser for 4 consecutive weeks.
• Willing to use Rejuvaskin Skin Recovery Cream once daily after using the - Rejuvaskin body cleanser for 4 consecutive weeks.
• Willing to maintain their current diet, skincare routine (aside from substitution of body wash and skin cream), and lifestyle habits for the study duration.
• Willing and able to take standardized photographs of an affected body area at Baseline and Week 4 using a personal smartphone.
• Able to read, understand, and complete questionnaires in English.
• Resides in the United States with a valid shipping address.
• Willing to provide informed consent and comply with all study procedures

Exclusion Criteria:

• Known allergy or sensitivity to any ingredient in the study product.
• Currently pregnant, breastfeeding, or planning to become pregnant during the study period.
• Active, severe skin condition on the body requiring prescription topical or systemic treatment (e.g., active severe atopic dermatitis flare under medical care, active infection at intended application sites).
• Currently using prescription topical corticosteroids, calcineurin inhibitors, or other prescription topical eczema treatments on the body, or initiation of such treatment planned during the study.
• Currently participating in another clinical or skincare research study, or planning to enroll during this study's duration. (